statistiche ricercatore

PASSAMONTI, FRANCESCO

Distribuzione geografica

Continente	#
NA - Nord America	25.914
EU - Europa	10.599
AS - Asia	7.331
SA - Sud America	925
Continente sconosciuto - Info sul continente non disponibili	550
AF - Africa	104
OC - Oceania	7
Totale	45.430

Salva come PNG Salva come JPEG

Nazione	#
US - Stati Uniti d'America	25.668
IT - Italia	5.674
SG - Singapore	2.218
CN - Cina	1.670
UA - Ucraina	1.568
TR - Turchia	1.031
VN - Vietnam	1.025
HK - Hong Kong	762
BR - Brasile	745
SE - Svezia	703
IE - Irlanda	613
DE - Germania	426
GB - Regno Unito	392
FI - Finlandia	350
FR - Francia	329
RU - Federazione Russa	260
BD - Bangladesh	201
CA - Canada	131
IN - India	89
MX - Messico	73
JP - Giappone	66
AR - Argentina	64
PK - Pakistan	47
NL - Olanda	44
CZ - Repubblica Ceca	41
AT - Austria	37
ES - Italia	35
PL - Polonia	35
IQ - Iraq	34
EC - Ecuador	33
ZA - Sudafrica	28
ID - Indonesia	26
SA - Arabia Saudita	22
CO - Colombia	20
UZ - Uzbekistan	19
VE - Venezuela	19
MY - Malesia	16
LT - Lituania	15
BE - Belgio	14
CL - Cile	13
EG - Egitto	11
EU - Europa	11
JO - Giordania	11
KR - Corea	11
MA - Marocco	11
NG - Nigeria	11
DZ - Algeria	10
PY - Paraguay	10
AE - Emirati Arabi Uniti	9
HN - Honduras	9
HU - Ungheria	9
KE - Kenya	9
NP - Nepal	9
PE - Perù	9
CR - Costa Rica	8
IR - Iran	8
BG - Bulgaria	7
CH - Svizzera	7
ET - Etiopia	7
IL - Israele	7
JM - Giamaica	7
KZ - Kazakistan	7
LB - Libano	7
TW - Taiwan	7
UY - Uruguay	7
MD - Moldavia	6
NO - Norvegia	6
OM - Oman	6
RS - Serbia	6
TH - Thailandia	6
PH - Filippine	5
SN - Senegal	5
TN - Tunisia	5
AU - Australia	4
AZ - Azerbaigian	4
BA - Bosnia-Erzegovina	4
RO - Romania	4
BO - Bolivia	3
DO - Repubblica Dominicana	3
GR - Grecia	3
NZ - Nuova Zelanda	3
TT - Trinidad e Tobago	3
AL - Albania	2
AO - Angola	2
BS - Bahamas	2
DK - Danimarca	2
GP - Guadalupe	2
GT - Guatemala	2
GY - Guiana	2
KW - Kuwait	2
LU - Lussemburgo	2
PA - Panama	2
PR - Porto Rico	2
PS - Palestinian Territory	2
PT - Portogallo	2
SK - Slovacchia (Repubblica Slovacca)	2
XK - ???statistics.table.value.countryCode.XK???	2
A2 - ???statistics.table.value.countryCode.A2???	1
BW - Botswana	1
CI - Costa d'Avorio	1
Totale	44.884

Salva come PNG Salva come JPEG

Città	#
Milan	4.221
Fairfield	3.291
Woodbridge	2.768
Ashburn	2.147
Houston	2.079
San Jose	1.601
Ann Arbor	1.578
Seattle	1.339
Jacksonville	1.338
Cambridge	1.176
Wilmington	1.125
Singapore	1.122
Hong Kong	748
Chandler	678
Dublin	610
Dallas	578
Princeton	526
Dearborn	479
Izmir	473
Nyköping	365
Boardman	337
The Dalles	315
Beijing	300
Dong Ket	271
Rome	252
Lauterbourg	235
San Diego	178
Ho Chi Minh City	160
Los Angeles	134
Ogden	133
Hanoi	125
New York	124
Santa Clara	117
London	98
Como	84
Council Bluffs	82
Guangzhou	81
Chicago	80
São Paulo	67
Washington	66
Redmond	64
Helsinki	61
Hefei	54
Mexico City	53
Orem	52
Tokyo	49
Waltham	49
Kocaeli	48
Nanjing	45
Hangzhou	44
Munich	44
Shanghai	40
Atlanta	38
San Francisco	38
Toronto	38
Kunming	37
Zhengzhou	36
Montreal	35
Brooklyn	33
Tianjin	31
Da Nang	30
Warsaw	30
Brno	29
Denver	29
Kilburn	29
Norwalk	29
Rio de Janeiro	29
Frankfurt am Main	27
Nuremberg	27
Boston	26
Columbus	26
Phoenix	26
Redwood City	25
Jinan	24
Chennai	23
Nanchang	23
Düsseldorf	21
Haiphong	20
Ankara	19
Salt Lake City	19
Changsha	18
Johannesburg	18
Tashkent	18
Belo Horizonte	17
Manchester	17
Quito	17
Rawalpindi	17
Verona	17
Memphis	16
Poplar	16
Stockholm	16
Turku	16
Vienna	16
Amsterdam	15
Chengdu	15
Dhaka	15
Acton	14
Brasília	14
Las Vegas	14
North Bergen	14
Totale	33.201

Salva come PNG Salva come JPEG

Nome	#
Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients	812
Clinical relevance of murine double minute 2 single nucleotide polymorphisms 309 in familial myeloproliferative neoplasm	290
A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence	282
Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study.	274
A gain-of-function mutation of JAK2 in myeloproliferative disorders	268
Analysis of three screening methods for the detection of calreticulin gene mutations	268
Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: An analysis by the MPN QOL international working group	249
Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts	248
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis	246
Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations	243
Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study	243
European LeukemiaNet. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.	241
Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN	241
Mutations and thrombosis in essential thrombocythemia: Prognostic interaction with age and thrombosis history	241
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis	240
Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients.	238
Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs	236
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications.	234
Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms	232
Subcutaneous 'lipoma-like' B-cell lymphoma associated with HCV infection: a new presentation of primary extranodal marginal zone B-cell lymphoma of MALT.	230
JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations.	230
New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma	229
Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group	227
Mutational status of myeloproliferative neoplasms.	223
Looking for CALR mutations in familial myeloproliferative neoplasms	223
The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients.	222
Bone marrow histology in marginal zone B-cell lymphomas: correlation with clinical parameters and flow cytometry in 120 patients	221
ACUTE MYELOID LEUKEMIA (AML) HAVING EVOLVED FROM ESSENTIAL THROMBOCYTHEMIA (ET): DISTINCTIVE CHROMOSOME ABNORMALITIES IN PATIENTS TREATED WITH PIPOBROMAN OR HYDROXYUREA	221
Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia	218
Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera	218
Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients	217
A new acute myeloid leukemia case with STAT5B-RARA gene fusion due to 17q21.2 interstitial deletion	217
Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis	215
Aspirin in pregnant patients with essential thrombocythemia: a retrospective analysis of 129 pregnancies	212
A novel germline JAK2 mutation in familial myeloproliferative neoplasms	211
Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia.	211
Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients.	210
Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms	208
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia	207
Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts	207
Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders	206
The 'GGCC' haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera.	205
Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patients	202
It is time to change thrombosis risk assessment for PV and ET?	201
TREATMENT OF POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTHEMIA: THE ROLE OF PIPOBROMAN.	201
Novel agents in indolent lymphomas	201
Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report	201
CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons	201
A prognostic model to predict survival in 867 WHO-defined essential thrombocythemia at diagnosis: a study by the IWG-MRT.	200
The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF)	200
European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis: Haematologica 2012;97(3):360-5 - Comment	200
Standard care and investigational drugs in the treatment of myelofibrosis	200
Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis--prognostic relevance is independent of IPSS or karyotype.	198
A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis	198
MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis	198
Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project	198
Developments in diagnosis and treatment of essential thrombocythemia	198
Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group	198
Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders	197
Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial	197
Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia	197
Driver mutations' effect in secondary myelofibrosis: An international multicenter study based on 781 patients	197
DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status.	196
Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2	196
Direct-Acting Antivirals During or After Immunochemotherapy in Hepatitis C Virus-Positive Diffuse Large B-Cell Lymphomas	196
Cerebral venous thrombosis and myeloproliferative neoplasms: results from two large databases	195
Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients	195
What are RBC-transfusion-dependence and -independence?	194
Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome.	194
Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman.	194
To the editor: In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology	194
Role of the molecular staging and response in the management of follicular lymphoma patients	193
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)	193
Flow-FISH evaluation of telomere length in Philadelphia-negative myeloproliferative neoplasms.	192
Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis	192
Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early /prefibrotic primary myelofibrosis.	190
Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study	190
Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin's lymphoma	190
How I treat polycythemia vera	190
A long-term time course of colorimetric assessment of the effects of imatinib mesylate on skin pigmentation: a study of five patients	189
Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: An international study of 264 patients.	189
Disease anticipation in familial myeloproliferative neoplasms.	189
Cardiovascular events and intensity of treatment in polycythemia vera	189
The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group	189
A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis	189
RBC-transfusion guidelines update	188
Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy	188
A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process	187
Individualizing Care for Patients With Myeloproliferative Neoplasms: Integrating Genetics, Evolving Therapies, and Patient-Specific Disease Burden	187
JAK inhibitor in CALR-mutant myelofibrosis	186
Prognostic factors and models in polycythemia vera, essential thrombocythemia, and primary myelofibrosis	186
SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub	186
Blast phase of essential thrombocythemia: A single center study.	184
Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS.	184
Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs	184
A final note about ibrutinib in relapsed or refractory CLL: Conclusive results from RESONATE sound definitely good!	183
New generation small-molecule inhibitors in myeloproliferative neoplasms	182
Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project	181
Myeloproliferative Neoplasms	181
Essential thrombocythemia and pregnancy: Observations from recent studies and management recommendations.	181
Totale	21.483

Salva come PNG Salva come JPEG

Categoria	#
all - tutte	182.505
article - articoli	0
book - libri	0
conference - conferenze	0
curatela - curatele	0
other - altro	0
patent - brevetti	0
selected - selezionate	0
volume - volumi	0
Totale	182.505

Salva come PNG Salva come JPEG

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	2.252	0	436	24	118	96	128	150	159	146	416	243	336
2022/2023	2.444	283	79	141	230	177	650	15	300	372	82	40	75
2023/2024	6.571	1.015	1.045	1.030	1.308	1.278	449	66	83	201	20	24	52
2024/2025	3.136	26	12	606	106	104	251	107	217	389	241	246	831
2025/2026	9.211	591	535	640	1.179	557	496	1.744	696	1.287	675	432	379
2026/2027	1.215	1.106	109	0	0	0	0	0	0	0	0	0	0
Totale													45.430